CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 346 enrolled
Drug / intervention
SIILPCV10 +2 morebiological
Likely dose
SIILPCV10 2 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02308540
NCT02308540Phase 2Completed

A Phase 1/2, Prospective,Randomized, Active-Controlled, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity of Serum Institute of India's PCV10 in Healthy Adults, Toddlers, and Infants

PATH·interventional·Posted Dec 4, 2014·Updated Aug 2, 2019

In Brief

A Phase 2 clinical trial evaluating SIILPCV10, Pneumovax 23, and 1 other intervention for Pneumococcal Disease. Completed, enrolled 346 participants across 1 site.

Detailed Summary

Phase 1/2, Prospective, Single Center, Randomized, ActiveControlled, Double-Blind, Age De-escalation Study to assess the safety and tolerability of SIILPCV10 administered as a single-dose regimen to healthy Gambian pneumococcal conjugate vaccine (PCV)-naïve young adults and PCV-primed toddlers through 4 weeks post vaccination. Each adult and toddler subject will undergo a total of 4 clinic visits. Each infant subject will undergo a total of 9 scheduled visits. Blood will be collected from all subjects during the screening visit for safety and potential immunological assessments, and 28 days after completion of the vaccination schedule for immunological assessments. For adults, the vaccine was given intramuscularly into the mid-deltoid muscle of nondominant arm using a 24-gauge needle. For toddlers and infants, the vaccine will be given IM into the anterolateral aspect of the left thigh. Blood will be collected from adults and toddlers for safety labs at the Day 7 post-vaccination visit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesThe Gambia
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 4, 2014
Enrollment StartJan 12, 2015
Primary CompletionApr 1, 2016
Study CompletionNov 3, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.6 years ago

Interventions

SIILPCV10biological

10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).

Pneumovax 23biological

23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.

Prevenar 13biological

13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts